Clinical Trials Logo

Clinical Trial Summary

Background: Bone marrow failure diseases are rare. Much is known about the diseases at the time of diagnosis, but long-term data about the effects of the diseases and treatments are lacking. Researchers want to better understand long-term outcomes in people with these diseases. Objective: To follow people diagnosed with acquired or inherited bone marrow failure disease and study the long-term effects of the disease and its treatments on organ function. Eligibility: People aged 2 years and older who have been diagnosed with acquired or inherited bone marrow failure or Telomere Biology Disorder. First degree family members may also be able to take part in the study. Design: Participants will be screened with a medical history, physical exam, and blood tests. They may have a bone marrow biopsy and aspiration. For this, a large needle will be inserted in the hip through a small cut. Marrow will be drawn from the bone. A small piece of bone may be removed. Participants may also be screened with some of the following: Cheek swab or hair follicle sample Skin biopsy Urine or saliva sample Evaluation by disease specialists (e.g., lung, liver, heart) Imaging scan of the chest Liver ultrasounds Six-Minute Walk Test Lung function test Participants will be put into groups based on their disease. They will have visits every 1 to 3 years. At visits, they may repeat some screening tests. They may fill out yearly surveys about their medicines, transfusions, pregnancy, bleeding, and so on. They may have other specialized procedures, such as imaging scans and ultrasounds. Participation will last for up to 20 years.


Clinical Trial Description

Study Description: This study will allow for the long term follow up of patients with acquired and inherited bone marrow failure, both treated and untreated. Objectives: Primary Objective The primary objective is to characterize disease and treatment related long-term outcomes in subjects with inherited or acquired marrow failure. Secondary Objectives 1. Rates of disease progression requiring intervention 2. Determine overall survival 3. Determine event free survival in subjects who receive treatment 4. Genetic or molecular biomarker to predict the long-term outcomes/early diagnosis in SAA and disease progression in other marrow failures. 5. Determine effects of pregnancy, viral infections, and vaccinations on disease course 6. Determine rates of both hematologic and solid organ malignancies 7. For Telomere Biology Disorders (TBD) cohort, assess the systemic impact of the disease including lung function, liver function, immunodeficiency, endocrine disorders, vascular disorders, and cardiovascular disease 8. For diseases with a genetic cause, determine the differences in clinical phenotype between different mutations causing the syndrome (example within TBD) 9. Family genetic studies to determine the incidence and penetrance of specific gene mutations within one family Tertiary/Exploratory Objectives 1. Genomic analysis (including whole exome or whole genome sequencing) to seek a potentially disease-causing mutations in subjects who meet the clinical phenotype for inherited disease but do not harbor a known mutation using sequencing 2. Serial assessment of hematopoiesis and immune activity as it relates to clinical course Endpoints: Primary Endpoints: Cohort 1 (SAA): Rate of relapse and clonal evolution in previously treated subjects. Cohort 2 (Other marrow failure): Rate of progression (cytopenias or clonal evolution) requiring therapeutic intervention. Cohort 3 Telomere Biology Disorders (TBD): Development of cytopenias, lung disease or liver disease, or (if present at baseline) characterization, and rate of progression of cytopenias, lung disease or liver disease in TBD subjects and looking at their overall contribution to morbidity and mortality. Cohort 4 Inherited Bone Marrow Failure (IBMF): Rate of progression to transfusion dependent marrow failure, marrow failure requiring therapeutic intervention (such as medical therapy or HSCT) or the progression to hematological or solid malignancy. Secondary Endpoints: Cohort 1 (SAA): 1. Response to treatment at 3 and 6 months and rates of relapse 2. Overall survival 3. Type and severity of additional medical diagnoses 4. Rates of clinically significant paroxysmal nocturnal hemoglobinuria (PNH) 5. Rates, timing, and treatment of abnormal iron status (iron overload or deficiency) 6. Rates and outcomes of pregnancy, and rate and treatment of abnormal menses 7. Rates of drug induced complications 8. Incidence of vaccination and rates of relapse following administration Cohort 2 (Other marrow failure): 1. Treatment response 2. Development of PNH and occurrence of symptoms, or need for therapy 3. Overall survival Cohort 3 (TBD): 1. Overall survival 2. Response to treatment in terms of improvement of cytopenias, or slower progression of lung or liver disease or fibrosis 3. Development of hematological or solid organ malignancy 4. Presence of an immunodeficiency or abnormal lab values (immunoglobulin or lymphocyte profile) 5. Presence of an endocrine disorder or abnormal hormonal levels 6. Presence of a vascular abnormality 7. Presence of an abnormal ECG or ECHO. Incidence of IHD over time 8. Presence, development of or rate of progression of cytopenias,lung disease, and liver disease compared between TBD causing mutations 9. Presence of TBD mutation in a family member and its association with cytopenias, short telomeres, and evidence of lung or liver involvement. Presence, development of or rate of progression of cytopenias, lung disease, and liver disease compared between family members with the same mutation 10. Genomic analysis using whole exome sequencing or whole genome sequencing to look for potentially disease causing variants in subjects who meet the clinical phenotype for TBD but do not have a known mutation Cohort 4 (IBMF): 1. Overall survival 2. Treatment response 3. Development of hematological or solid organ malignancy 4. New medical diagnosis and its relationship to any treatment received 5. Record PNH incidence in IBMF as defined by a clone size of >1% in granulocytes 6. Determine the incidence of iron overload, its course with any IBMF treatments, and its response to chelation therapy 7. Record the outcomes of pregnant subjects 8. The presence of viral and bacterial infections and correlation to worsening cytopenias. Presence of worsening cytopenias after vaccination 9. Presence of IBMF mutation in a family member and its association with cytopenias, and other clinical phenotypes 10. Genomic analysis using whole exome sequencing or whole genome sequencing to look for potentially disease causing variants in subjects who meet the clinical phenotype for TBD but do not have a known mutation ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05012111
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact Katherine C Roskom, R.N.
Phone (301) 451-7094
Email katherine.roskom@nih.gov
Status Recruiting
Phase
Start date October 25, 2021
Completion date February 4, 2041

See also
  Status Clinical Trial Phase
Recruiting NCT02828592 - Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Phase 2
Completed NCT02833805 - NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia Phase 2
Terminated NCT01319851 - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT00004143 - Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Phase 2
Recruiting NCT03836690 - Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation Phase 1
Recruiting NCT06039436 - Conditioning Regimen Containing Low Dose ATG for The Treatment of Acquired SAA Receiving sUCBT
Enrolling by invitation NCT05049668 - RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial
Recruiting NCT01472055 - Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation Phase 2
Recruiting NCT01351545 - A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Completed NCT01703169 - Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia Phase 2
Withdrawn NCT01129323 - Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia N/A
Completed NCT00516152 - Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT Phase 2
Recruiting NCT06069180 - The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA Phase 4
Recruiting NCT03579875 - Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders Phase 2
Recruiting NCT05720234 - Avatrombopag Combined With IST as First-line Treatment for SAA Phase 2
Recruiting NCT04304820 - Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) Phase 2
Terminated NCT00358657 - Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders Phase 2
Completed NCT02998645 - Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia Phase 2
Active, not recruiting NCT03825744 - Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia Phase 3
Not yet recruiting NCT06279494 - Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors Phase 1/Phase 2